BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 81.9%

Neg 0% Neu 81.9% Pos 0%

BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and maintains $22 price target.

Comments

No comments yet. Be the first!